Emerging SARS-CoV-2 Resistance After Antiviral Treatment.

ABSTRACT:

Importance

Previous studies have identified mutations in SARS-CoV-2 strains that confer resistance to nirmatrelvir, yet how often this resistance arises and its association with posttreatment virologic rebound is not well understood.

Objective

To examine the prevalence of emergent antiviral resistance after nirmatrelvir treatment and its association with virologic rebound.

Design, setting, and participants

This cohort study enrolled outpatient adults with acute COVID-19 infection from May 2021 to October 2023. Participants were divided into those who received antiviral therapy and those who did not. The study was conducted at a multicenter health care system in Boston, Massachusetts.

Exposure

Treatment regimen, including none, nirmatrelvir, and remdesivir.

M

SUBMITTER: Tamura TJ 

PROVIDER: S-EPMC11425144 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature